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a  b  s  t  r  a  c  t
Objective:  Diastolic  dysfunction  (DD)  is  a frequent  condition  in  hypertensive  patients  whose  presence
increases  mortality  and  whose  treatment  remains  unclear.  The  aim of  this  study  was  to  investigate  in a
prospective,  double-blinded,  placebo-controlled  randomized  design  the  additive  effect  of  simvastatin  on
DD  in enalapril-treated  hypertensive  patients  with  average  cholesterol  levels.
Methods: Hypertensive  patients  with  DD  and  LDL-cholesterol  <160  mg/dL  underwent  a run-in  phase  to
achieve  a  systolic  blood  pressure  (SBP)  <135  mmHg  and  diastolic  blood  pressure  (DBP)  <85 mmHg  with
enalapril.  Hydrochlorothiazide  was  added  when  need  to achieve  blood  pressure  control.  Four  weeks  after
reaching  the  optimum  anti-hypertensive  regimen  patients  were  randomized  to  receive  80  mg  simvastatin
(n  =  27)  or  placebo  (n =  28) for a period  of 20 weeks.  Echocardiograms  were  performed  before  and  after
treatment  with  measurement  of  maximum  left  atrial  volume  (LAV),  conventional  and  tissue  Doppler
velocities  in  early  diastole  (E,  e′)  and  late  diastole  (A, a′).
Results: After  20 weeks,  the  simvastatin  group  presented  reduction  in  SBP  (−4  ±  2 mmHg,  p =  0.02),
increase  in  E/A  ratio  (1.0  ±  0.05  to  1.2  ±  0.06, p =  0.03)  and  decrease  of LAV  indexed  to  body  surface  area
2(24.5  ±  0.9  to  21.1  ± 0.8  ml/m , p  =  0.048),  as  compared  with  placebo  arm.  No  change  in systolic  func-
tion  and  no  correlation  between  the  E/A  ratio,  LAV  and  changes  in blood  pressure  or lipid proﬁle  were
observed.
Conclusions:  The  addition  of simvastatin  to  enalapril  in  hypertensive  patients  with  average  cholesterol  lev-
els  improves  parameters  of  diastolic  function  independently  of changes  in  blood  pressure  or cholesterol.
© 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.. Introduction
Diastolic dysfunction (DD) is the most common and early form
f hypertension target lesion seen in clinical practice [1]. Its pres-
nce is related to higher morbidity and mortality which may  be
ndependent of blood pressure (BP) levels or the degree of left ven-
ricular hypertrophy (LVH) [1,2]. Despite the frequency and clinical
elevance, the reversal of DD remains a challenge. Intensive BP-
owering [3] and the inhibition of the rennin–angiotensin system
RAS) [4,5] have both been demonstrated to attenuate DD through
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Open access under the Elsevier OA license.their beneﬁcial effects on left ventricular hypertrophy and ﬁbro-
sis. There is evidence, however, indicating that the DD can persist
partially or completely in a substantial number of patients with BP
under control and treated by RAS inhibitors, indicating the need for
complementary treatments [5].
In animal models, treatment with statins has been reported to
reduce hypertrophy and interstitial ﬁbrosis in the left ventricle
(LV) with consequent improvement of diastolic function [6,7]. To
date, however, such effects have not been conﬁrmed in random-
ized controlled clinical trials. Moreover, it is unknown whether
the effect of statin in DD is additive or not to the effect of ACE
inhibitors.
Thus, the aim of this study was to investigate in a prospec-
tive, double-blinded, placebo-controlled randomized design the
additive effect of simvastatin on enalapril on DD, assessed by
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.1. Endpoints
The prespeciﬁed primary endpoints were changes in ratio of
he early (E) to late (A) transmitral peak velocity (E/A ratio) and
n early diastolic mitral annular velocity (e′). Secondary endpoints
ere changes in systolic blood pressure (SBP), diastolic blood pres-
ure (DBP), maximum left atrial volume (LAV), LV mass, LV wall
hickness, E-wave deceleration time (E-DT), E/e′ ratio and mitral
nnulus systolic velocity (s). This report satisﬁes the recommended
eporting guidelines for randomized controlled trials [8].
.2. Sample size calculation and patients’ selection
The sample size calculation took into account a 90% power and
n alpha error of 5%. By these criteria, it was predicted the need of
andomizing 42 patients divided in two arms to detect a mean dif-
erence of 0.19 ± 0.25 cm/s in the E/A ratio [4] and a mean difference
f 3 ± 2 cm/s in the e′ velocity [9].
Inclusion criteria were hypertensive [10] men or post-
enopausal women aged between 40 and 65 years old,
asting blood glucose <100 mg/dL and glucose tolerance test
140 mg/dL, waist circumference <102 cm (men) or < 88 cm
women), triglycerides <150 mg/dL, LDL-cholesterol ≤160 mg/dL,
reatinine <1.2 mg/dL, sinus rhythm, the presence of grade 1 or
 of DD with an LV ejection fraction (EF) > 55% and absence of
yocardial ischemia during dobutamine stress echocardiography.
he DD was considered in the presence of E-DT > 240 ms  and E/A
atio < 0.9 and septal e′ < 10 cm/s (grade 1 or impaired relaxation)
r E-DT = 160–240 ms,  E/A ratio = 0.9–2.0, and septal e’ < 8 cm/s
n association with the LAV index ≥28 ml/m2, septal E/e′ ≥ 15 or
ositive Valsalva maneuver (grade 2 or pseudonormal pattern)
11]. Exclusion criteria were thyroid dysfunction, acute or chronic
iver disease, regular use of 3 or more antihypertensive drugs,
econdary hypertension, symptoms or history of atherosclerotic
isease, valvular dysfunction and use of statins in the last 6 months.
From 2006 to 2009, we evaluated 359 consecutive hyperten-
ive men  and women enrolled at the Brasilia’s Health Department’s
egistry and who underwent detailed clinical examination and
chocardiogram screening in order to select those who met  all
nclusion criteria. From this clinical screen, 62 patients were
elected and accepted to participate in the study. The Institutional
thics Committee approved the study and all participants signed
he informed consent.
.3. Study protocol
During the run-in phase, patients were treated by enalapril,
hich dose was adjusted weekly to achieve SBP ≤ 135 mmHg  and
BP ≤ 85 mmHg. Hydrochlorothiazide 25 mg/day was added in 25
atients to achieve BP control. Seven patients were excluded
ecause they require the addition of other antihypertensive drugs
n = 3) or had a persistent cough after enalapril (n = 4). Having
eached the target SBP and DBP for four consecutive weeks in
onstant use of the same dose of antihypertensive drugs, patients
nderwent the drug treatment phase of the study and were allo-
ated to simvastatin 80 mg/day (Zocor®, Merck, Sharp & Dohme,
ão Paulo, Brazil; n = 27) or placebo (n = 28) using block randomiza-
ion stratiﬁed for gender during a treatment period of 20 weeks.
During experimental phase, patients were evaluated regularly
very 4 weeks for assessment of BP, treatment adherence and
resence of adverse effects. The study drugs were provided at
ach visit and treatment adherence was checked by counting pills
emaining from the previous 4 weeks. The average of at least
wo measures of BP, after 10 min  of rest, with properly calibratedsis 222 (2012) 444– 448 445
sphygmomanometer was  obtained [10]. Anti-hypertensive treat-
ment was adjusted as necessary to maintain therapeutic goal.
2.4. Biochemical analyses
Every 8 weeks, the following measurements were performed:
total cholesterol (CHOD-PAP, Roche Diagnostics, Mannheim,
Germany), triglycerides (GPO-PAP, Roche Diagnostics, Mannheim,
Germany), high-density lipoprotein (HDL) cholesterol (Roche Diag-
nostics, Mannheim, Germany), creatine phosphokinase (CPK), and
alanine (ALT) and aspartate (AST) aminotransferases (Roche Diag-
nostics, Mannheim, Germany). LDL-cholesterol was  calculated by
the Friedewald formula. During the study, the results were made
available exclusively for the Safety Monitoring Committee.
2.5. Echocardiography
All examinations were conducted by one experienced physi-
cian echocadiographer (A.L.S.B) who were blinded for the patient’s
experimental treatment. A comprehensive 2-dimensional and
Doppler echocardiogram (HDI 5000, Philips ATL, Bothell, WA)  using
2/4 MHz  transducer and second harmonic imaging was carried
out in the morning period in all patients at the beginning and
end of experimental treatment. BP was  measured at the time of
echocardiographic exam initiation. LV M-mode measurements of
wall thickness and end-diastolic and end-systolic diameters were
used for calculation of fractional shortening, relative wall thick-
ness (RWT) and LV mass, which was indexed to body surface area
(BSA) [12]. LV remodeling was  deﬁned as RWT  ≥ 0.42 and LVH
was  deﬁned as LV mass index was >115 g/m2 in men or >95 g/m2
in women, respectively [12]. LV EF was  determined by Teichholz
method [12]. LAV was calculated by modiﬁed Simpson’s method
on the apical 4 and 2 chambers and indexed to BSA (LAVi) [12]. LAV
was  measured in the frame just before mitral valve opening exclud-
ing the LA appendage and pulmonary veins. The plane of mitral
annulus deﬁned the LA inferior border. Mitral inﬂow velocities
were recorded in the apical 4-chamber view with the pulsed-wave
Doppler sample volume placed at the level of the mitral valve tips.
The peak velocity of early (E) and late (A) diastolic waves and the E-
DT were measured. The E/A ratio was calculated at rest and during
Valsalva maneuver. The peak myocardial systolic (s′), early dias-
tolic (e′), and late diastolic (a′) velocities were measured in the
apical 4- and 2-chamber views using Doppler tissue imaging (DTI)
with a 2 mm sample volume placed at the at the septal, lateral,
anterior and inferior mitral annulus. All DTI parameters were con-
sidered the average of these four sites. Mean E/e′ was  calculated.
All Doppler measurements were obtained during expiratory apnea.
All data were stored on optical disk and an independent physician,
blinded to clinical data and image process, performed the analyses
off line. All values were the average of 3 beats.
Measurements of LAV and of conventional and tissue Doppler
at rest were repeated in 10 patients by the same observer who
performed the initial measures and by a second observer equally
unaware of patient data to verify the intra- and inter-observer
variability. The coefﬁcients of intra-observer and inter-observer
variability were 0.77% and 1.04% for the Doppler measurements,
and 1.1% and 3.8% for LAV measurements, respectively.
2.6. Statistical methods
Patients, researchers and analysts of the results were blind to the
echocardiographic ﬁndings and to the treatment used. Statistical
analyses were performed using JMP  and SAS 9.2 software applica-
tions (SAS Institute, Cary, NC, USA). All the analyses were performed
on an intention to treat basis and were adjusted for gender and age.
Continuous variables were presented as mean ± standard deviation
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Table 1
Baseline characteristics of patients in the study groups.
Characteristics Placebo (n = 28) Statin (n= 26) p
Age, years 54 ± 1.1 54.2± 1.1 0.93
Male,  n (%) 15 (54) 13(50) 1.00
Smoking, n (%) 3 (11) 4 (15) 0.69
Body  mass index (kg/m2) 27 ± 1 26 ± 1 0.51
Family  history of CAD, n (%) 5 (17.9) 0 (0) 0.05
Waist  circumference (cm) 93 ± 1 91 ± 1 0.16
Sedentary, n (%) 11 (41) 16 (59) 0.17
Left  ventricular hypertrophy, n (%) 2 (7.1) 0 (0) 0.49
Left  ventricular remodeling, n (%) 1 (3.5) 3 (11.5) 0.35
Framingham risk score, % in 10 years 6.5 ± 0.9 6.5 ±1.3 0.86
Time  from hypertension diagnosis (years) 11.3 ± 1.3 12.2 ± 1.6 0.67
Time  of treatment for hypertension (years) 10.2 ± 1.0 11.5 ± 1.5 0.81
Medications prior to the study
ACE Inhibitors, n (%) 27(96) 23 (88) 0.34
Beta  blockers, n (%) 2 (7) 4 (15) 0.41
Diuretics, n (%) 9 (32) 13 (50) 0.18
Blood  pressure prior to the study entry
SBP (mmHg) 129 ± 14 137 ± 20 0.07
DBP  (mmHg) 77 ± 11 81 ± 14 0.14


















CEnalapril dose (mg/day) 24 ± 2 
Use  of hydrochlorothiazide, n (%) 15 (54) 
nd categorical variables as absolute number (n) and frequencies
%). Statistical signiﬁcance was considered p < 0.05. Differences in
aseline characteristics between groups were evaluated with the
tudent t test or the nonparametric Mann–Whitney test for con-
inuous variables and the chi-square test for categorical variables.
omparisons between the groups regarding the effects of treat-
ents on BP, lipid proﬁle and echocardiographic variables were
ade by the Student t test for comparison variations between
roups and within each group. To compare the dose of enalapril,
 logarithmic scale was used to normalize the distribution. To eval-
ate the correlation between changes in diastolic parameters and
ariations in BP and lipid proﬁle, we used the linear correlation
oefﬁcient of Pearson.
. Results.1. Clinical baseline and follow-up data
Clinical data at the time of randomization are shown in
ables 1 and 2 (baseline). There was no signiﬁcant difference
able 2
hanges in SBP, DBP, heart rate and lipid proﬁle during the experimental treatment.
Baseline 4 weeks 8 weeks 
SBP (mmHg)
Placebo 125 ± 2 129 ± 3 124 ± 3 
Statin  130 ± 3 127 ± 3 128 ± 3 
DBP (mmHg)
Placebo 73 ± 2 76 ± 2 73 ± 1 
Statin  73 ± 2 76 ± 2 75 ± 2 
Heart  rate (bpm)
Placebo 71 ± 2 71 ± 2 67 ± 2 
Statin  68 ± 2 67 ± 1 70 ± 1 
LDL-cholesterol (mg/dL)
Placebo 122 ± 5 – 124 ± 6 
Statin  119 ± 6 – 74 ± 5‡
HDL-cholesterol (mg/dL)
Placebo 51 ± 3 – 51 ± 2 
Statin  47 ± 3 – 48 ± 2 
Triglycerides (mg/dL)
Placebo 114 ± 11 – 117 ± 12 
Statin  117 ± 11 – 102 ± 9 
* p < 0.05.
** p < 0.001.
‡ p < 0.0001 for the difference between treatment groups.24 ± 5 0.99
10 (39) 0.29
between the groups. However, family history of coronary disease
tended to be more frequent in the placebo group. Only two patients
had LVH and four had LV remodeling. During the experimental
phase, one patient of the simvastatin group was excluded after
manifesting acute thyroiditis. Therefore, 54 patients completed the
study. Adherence to therapy was  100% in both groups.
After run-in period, patients started the experimental phase of
the study with an adequate control of BP (Table 2). The daily doses
of enalapril were equivalent at randomization (Table 1) and at the
end of the study in the placebo and simvastatin (27 ± 2 mg/day
vs. 26 ± 2 mg/day; inter groups p = 0.9, respectively). The frequency
of the use of hydrochlorothiazide were equivalent in both groups
at randomization (Table 1) and during the experimental phase
(54% vs. 39%, inter groups p = 0.67). There was no difference in the
baseline measure and no change in BMI  during the experimental
period in both placebo and simvastatin arms (−0.1 ± 0.1 kg/m2 vs.
0.03 ± 0.1 kg/m2; inter groups p = 0.65, respectively).
As expected, the statin group presented a reduction of LDL-
cholesterol and triglyceride levels, reaching signiﬁcance from
the 8th and 20th weeks, respectively (Table 2). The levels of
12 weeks 16 weeks 20 weeks Variation
124 ± 2 122 ± 3 129 ± 3 5 ± 3
127 ± 3 124 ± 2 126 ± 3* −4 ± 2*
72 ± 1 74 ± 2 75 ± 2 2 ± 2
76 ± 2 74 ± 2 74 ± 2 2 ± 2
67 ± 2 68 ± 2 71 ± 2 −0.4 ± 2.4
67 ± 1 67 ± 2 68 ± 2 −0.2 ± 2.7
– 129 ± 6 130 ± 6 10 ± 5
– 75 ± 4‡ 78 ± 5‡ −41 ± 6‡
– 50 ± 2 47 ± 2 −3 ± 1
– 47 ± 2 46 ± 2 −2 ± 2
– 113 ± 13 129 ± 13 15 ± 8
– 91 ± 6 94 ± 7** −23 ± 11**
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Table 3
Echocardiographic changes during treatment with simvastatin or placebo.
Placebo (n = 28) Statin (n = 26) Variation
Variables Baseline 20th week Baseline 20th week Placebo Statin Inter groups p
Indexed LAV (ml/m2) 23.5 ± 1.0 23.2 ± 1.1 24.5 ± 0.9 21.1 ± 0.8 −0.3 ± 1.2 −3.3 ± 0.9** 0.048
Septal thickness (mm) 8.54 ± 0.84 8.19 ± 0.84 8.48 ± 0.81 8.10 ± 0.89 −0.34 ± 0.91* −0.38 ± 0.85* 0.88
Posterior wall thickness (mm) 8.66 ± 0.84 8.19 ± 0.84 8.55 ± 0.81 8.15 ± 0.89 −0.47 ± 0.89* −0.39 ± 0.82* 0.76
LV  diastolic diameter (mm) 48.4 ± 0.7 49.1 ± 0.7 46.7 ± 0.7 48.4 ± 0.7 0.69 ± 0.4 1.69 ± 0.4** 0.12
LV  systolic diameter (mm) 29.3 ± 0.6 29.0 ± 0.6 28.6 ± 0.6 29.0 ± 0.6 −0.28 ± 0.3 0.42 ± 0.45 0.15
LV  ejection fraction (%) 69.3 ± 0.9 71.3 ± 0.9 68.7 ± 0.9 70.0 ± 1.0 2.1 ± 0.8 1.3 ± 0.9 0.53
Relative wall thickness 0.35 ± 0.0 0.33 ± 0.0 0.36 ± 0.0 0.34 ± 0.0 −0.02 ± 0.0* −0.03 ± 0.0** 0.71
Indexed LV mass (g/m2) 81 ± 3 79 ± 3 78 ± 3 76 ± 3 −2 ± 3 −1.8 ± 3.1 0.94
Conventional Doppler
Transmitral E velocity (cm/s) 64 ± 3 66 ± 3 63 ± 4 69± 4 2.3 ± 2.7 5.4 ± 2.4* 0.37
Transmitral A velocity (cm/s) 63 ± 3 64 ± 3 65 ± 3 63 ± 4 0.9 ± 2.6 −2.7 ± 2.9 0.37
E/A  ratio 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.2 ± 0.1 0.0 ± 0.05 0.2 ± 0.1** 0.03
E  deceleration time (ms) 242 ± 12 222 ± 10 229 ± 10 216 ± 10 −12 ± 3 −14 ± 3 0.93
Tissue Doppler
Peak velocity of e′ (cm/s) 9.7 ± 0.6 10.1 ± 0.6 9.6 ± 0.6 10.2 ± 0.5 0.3 ± 0.3 0.6 ± 0.3 0.51
Peak  velocity of a′ (cm/s) 10.5 ± 0.3 10.5 ± 0.3 10.0 ± 0.3 10.1 ± 0.3 −0.02 ± 0.3 0.08 ± 0.3 0.76
Peak  velocity of s (cm/s) 8.8 ± 0.4 9.0 ± 0.5 8.6 ± 0.5 8.9 ± 0.5 0.2 ± 0.2 0.2 ± 0.2 0.84








































pE/e′ ratio 6.9 ± 0.4 6.9 ± 0.4 7.1 ±
ntra-group differences: *p < 0.05, **p < 0.001; LAV: left atrial volume; LV: left ventr
DL-cholesterol did not change signiﬁcantly in either group
Table 2). There was a signiﬁcantly difference in the changing of
BP in the statin group as compared to the placebo group reaching
igniﬁcance at the 20th week (Table 2). There was  a signiﬁcantly
reater reduction in SBP in the statin group compared to the placebo
roup reaching signiﬁcance at the 20th week (Table 2). The changes
n DBP and in heart rate during the experimental phase were not
igniﬁcantly different between groups. There was  a moderate and
igniﬁcant positive correlation between changes in SBP and in LDL-
holesterol in the statin group (r = 0.54, p = 0.004).
In the statin group, one patient complained of nausea and three
atients manifested hypotension requiring the reduction of the
ntihypertensive dose. In the placebo group one patient had nausea
nd diarrhea that remitted spontaneously. Elevation of ALT was sig-
iﬁcantly higher in the statin group than the placebo group (statin:
8 ± 3 to 54 ± 4 U/L vs. placebo: 38 ± 3 to 42 ± 3 U/L; p < 0.05). There
as no signiﬁcant difference in the elevation of AST (statin: 19 ± 1
o 31 ± 2 U/L vs. placebo: 19 ± 1 to 24 ± 2 U/L; p = NS) and CPK
statin: 89 ± 7 to 117 ± 14 U/L vs. placebo: 102 ± 10 to 162 ± 27 U/L;
 = NS) between the groups.
.2. Echocardiography
At randomization, there was no signiﬁcant difference in
chocardiographic parameters between the groups (Table 3). After
0 weeks, there was a slight but signiﬁcant reduction in poste-
ior wall thickness, interventricular septum thickness and relative
hickness of the LV in both groups (p < 0.05) but there were no
ifferences between groups.
The statin group presented increase in E/A ratio (1.0 ± 0.05
o 1.2 ± 0.06, intra group p = 0.005 and inter groups p = 0.03)
nd decrease of LAVi (24.5 ± 0.9 to 21.1 ± 0.8 ml/m2, intra group
 < 0.001, inter group p = 0.048), as compared with placebo arm. The
ifference between groups in E/A ratio and LAVi were signiﬁcant
ven after adjustment for gender, age and baseline values (p < 0.05).
lso, it was observed slight but signiﬁcant increases in E veloc-
ty (p = 0.04) and trend to increase e′ velocity (p = 0.05), however,
hese changes did not reach statistical signiﬁcance in the compar-
son between groups. There were no signiﬁcant differences in the
hanges of other Doppler diastolic (A, a’, e/a ratio, E/e’ ratio) or
ystolic(s) variables between the groups (Table 3). No signiﬁcant
orrelations between the E/A ratio, LAVi and changes in BP or lipid
roﬁle were observed.7.1 ± 0.4 −0.0 ± 0.2 −0.1 ± 0.3 0.99
4.  Discussion
This is the ﬁrst randomized, double-blind, placebo-controlled
study designed to evaluate the effect of statins on DD parameters
of hypertensive patients with average cholesterol levels and with
blood-pressure controlled by RAS inhibitor. The major new ﬁnding
of this research is that statins improves parameters of LV diastolic
function in such patients. Although the effect on diastolic function
parameters was  small in magnitude, the potential relevance of this
effect was reﬂected by the signiﬁcant reduction of the LAV.
As expected, enalapril treatment reduced the relative thickness
of the LV. Importantly, such reversal LV remodeling was  mostly
observed in patients in early stage of hypertension. In parallel to
this RAS inhibitor effect, patients who  also received simvastatin
had signiﬁcant increase of E/A ratio and decrease of the LAVi. Con-
sistently, the e′ wave presented a trend to increase in the group
treated by simvastatin, but not in the placebo group. For the latter,
however, the study was  not powered enough to detect inter groups
difference.
In normotensive, hypercholesteromic individuals, previous
investigations of the statin effect on DD have shown conﬂict-
ing results [13–15].  The limited sample size, the nonrandomized
uncontrolled design and the difference in the clinical background
between these investigations and the present study hampers any
comparison of results.
Isolated increase of the E/A ratio does not necessarily indi-
cate attenuation of DD. It may  indicate a pseudonormalization
of E/A ratio by increasing the ﬁlling pressures of the LV [11].
In the pseudonormalization, however, as the LV ﬁlling pressure
increases, the volume of LA increases [16]. Hence, in the presence
of LAV reduction, the concomitant increase in the E/A ratio suggests
decrease in the LV ﬁlling pressure and therefore the improvement
of the diastolic function.
The change in E/A ratio and LAV did not correlate with the
change in BP or in the relative thickness of the LV, suggesting that
the action of statin on the DD, in this well-treated hypertensive
population, is at least partly independent of its anti-hypertensive
effect and its effect on the regression of the LV mass. Although a
reduction in BP and LV mass are undoubtedly important determi-
nants of improvement in diastolic function [3,5], evidences indicate
that regression of myocardial ﬁbrosis also play a signiﬁcant and
independent role [4].  In fact, myocardial ﬁbrosis is associated with
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In the mechanistic standpoint, studies in animal models have
emonstrated that statins reduce myocardial ﬁbrosis by increas-
ng the bioavailability of nitric oxide, reducing inﬂammation, RAS
ctivity, oxidative stress and content of collagen type I in the LV wall
6,7]. This effect seems to be at least partially independent of plasma
holesterol lowering. In parallel, LAV has a positive correlation with
he time constant of relaxation [19]. Thus, as not mutually exclusive
echanisms, it is possible that the effect of statins on the DD occurs
y a combined effect on LV stiffness and relaxation. Nevertheless,
urther studies are required to conﬁrm this assumption.
Consistent with a recent meta-analysis [20], we observed a
igniﬁcant reduction in rest peripheral SBP after treatment with
tatins. In the present study, however, in contrast with a prior study
n our group [21], the reduction only reached statistical signiﬁ-
ance for SBP. Possibly the lower levels of plasma cholesterol and
BP in the present study participants and the adjustment of anti-
ypertensive medications to keep SBP and DBP under control may
ave caused the difference in results. It is plausible to infer that part
f the effect of the statin treatment in attenuating DD has elapsed
rom SBP reduction. Even in the absence of correlation between the
hange in SBP and changes in parameters of diastolic function, the
ole of SBP cannot be ruled out.
In interpreting our results, certain limitations must be consid-
red. Firstly, despite the reversal of DD have been demonstrated
n animal models after 8 weeks of treatment with statins [6],  the
ime required to verify the maximal effect of statins on the DD of
ypertensive individuals remains unknown. Secondly, the marginal
tatistical signiﬁcance we found in some results suggests that the
ample size may  have been underestimated and hidden subtle dif-
erences between the groups. Thirdly, as the study was conducted
n a speciﬁc population, our ﬁndings cannot be extrapolated to
atients with other diseases that directly or indirectly inﬂuence
he diastolic function such as diabetes mellitus or obesity. To com-
ensate these limitations, the study was assessed in a rigorous
andomized, double-blind, placebo-controlled.
In hypertensive patients, observational studies have indicated
hat for each decrease of 0.3 in the E/A ratio there is a 21% increase
n the risk of cardiovascular events [2].  In parallel, the increase
f the LAV independently predicts the incidence of atrial ﬁbrilla-
ion, heart failure, stroke and cardiovascular death even in patients
ithout known cardiovascular disease [22]. Hence, even such small
ncrease in E/A ratio and reduction of LAV, as observed in this study,
eserves consideration for its potential clinical impact. Still, stud-
es with clinical endpoints in hypertensive patients with DD are
equired to conﬁrm such a new target for statin treatment.
In conclusion, in this randomized, double-blind, placebo-
ontrolled clinical trial, a 20-week period of treatment with
imvastatin at high dose (80 mg/day) increases the E/A ratio and
ecreases the LAV in hypertensive individuals presenting DD and
verage cholesterol levels.
cknowledgements
This article is the product of a PhD thesis defended by ALSB
nder the supervision of ACS at the Post-Graduate Program in Car-
iology of the University of São Paulo Medicine School. The study
as funded by the Foundation for Research Support of the Distrito
ederal (FAP-DF) and the Program for Support of Post-Graduation
PROAP) of the Coordination for the Improvement of Higher Edu-
ation Personnel (CAPES) for the University of São Paulo. ACS was
upported by a fellowship grant of productivity in research from
[sis 222 (2012) 444– 448
the Brazilian National Research Council (CNPq). There was no addi-
tional funding and the authors have no conﬂict of interest for this
study.
References
[1] Redﬁeld MM,  Jacobsen SJ, Burnett Jr JC, et al. Burden of systolic and dias-
tolic ventricular dysfunction in the community: appreciating the scope of the
heart failure epidemic. JAMA: The Journal of the American Medical Association
2003;289:194–202.
[2] Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic signiﬁcance of left ven-
tricular diastolic dysfunction in essential hypertension. Journal of the American
College of Cardiology 2002;39:2005–11.
[3] Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin recep-
tor blockade and antihypertensive drugs on diastolic function in patients
with hypertension and diastolic dysfunction: a randomised trial. Lancet
2007;369:2079–87.
[4] Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial ﬁbro-
sis  in patients with hypertensive heart disease. Circulation 2000;102:1388–93.
[5] Wachtell K, Bella JN, Rokkedal J, et al. Change in diastolic left ventricular
ﬁlling after one year of antihypertensive treatment: the Losartan Inter-
vention for Endpoint Reduction in Hypertension (LIFE) Study. Circulation
2002;105:1071–6.
[6] Chang SA, Kim YJ, Lee HW,  et al. Effect of rosuvastatin on cardiac remodeling,
function, and progression to heart failure in hypertensive heart with estab-
lished left ventricular hypertrophy. Hypertension 2009;54:591–7.
[7]  Xu Z, Okamoto H, Akino M,  et al. Pravastatin attenuates left ventricular remod-
eling and diastolic dysfunction in angiotensin II-induced hypertensive mice.
Journal of Cardiovascular Pharmacology 2008;51:62–70.
[8] Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommen-
dations for improving the quality of reports of parallel-group randomized trials.
Annals of Internal Medicine 2001;134:657–62.
[9] Galderisi M,  Cicala S, Caso P, et al. Coronary ﬂow reserve and myocardial
diastolic dysfunction in arterial hypertension. American Journal of Cardiology
2002;90:860–4.
10] Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure. Hypertension 2003;42:1206–52.
11] Lester SJ, Tajik AJ, Nishimura RA, et al. Unlocking the mysteries of diastolic
function: deciphering the Rosetta Stone 10 years later. Journal of the American
College of Cardiology 2008;51:679–89.
12] Lang RM, Bierig M,  Devereux RB, et al. Recommendations for chamber quantiﬁ-
cation: a report from the American Society of Echocardiography’s Guidelines
and Standards Committee and the Chamber Quantiﬁcation Writing Group,
developed in conjunction with the European Association of Echocardiography,
a  branch of the European Society of Cardiology. Journal of the American Society
of  Echocardiography 2005;18:1440–63.
13] Talini E, Di Bello V, Bianchi C, et al. Early impairment of left ventricular func-
tion in hypercholesterolemia and its reversibility after short term treatment
with rosuvastatin A preliminary echocardiographic study. Atherosclerosis
2008;197:346–54.
14] Qie L, Meng X, Wang Y, et al. Assessment of regional systolic and diastolic func-
tions affected by atorvastatin in coronary artery disease using tissue Doppler
imaging. Clinical Cardiology 2008;31:551–5.
15] Mizuguchi Y, Oishi Y, Miyoshi H, et al. Impact of statin therapy on left ventricular
function and carotid arterial stiffness in patients with hypercholesterolemia.
Circulation Journal 2008;72:538–44.
16] Tsang TS, Barnes ME,  Gersh BJ, et al. Left atrial volume as a morphophysiologic
expression of left ventricular diastolic dysfunction and relation to cardiovas-
cular risk burden. American Journal of Cardiology 2002;90:1284–9.
17] Lindsay MM,  Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic
dysfunction and ﬁbrosis in hypertension. Hypertension 2002;40:136–41.
18] Martos R, Baugh J, Ledwidge M,  et al. Diastolic heart failure: evidence of
increased myocardial collagen turnover linked to diastolic dysfunction. Cir-
culation 2007;115:888–95.
19] Matsuda M, Matsuda Y. Mechanism of left atrial enlargement related to ventric-
ular diastolic impairment in hypertension. Clinical Cardiology 1996;19:954–9.
20]  Strazzullo P, Kerry SM,  Barbato A, et al. Do statins reduce blood pressure? A
meta-analysis of randomized, controlled trials. Hypertension 2007;49:792–8.
21] Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood
pressure after cholesterol-lowering treatment by statins (lovastatin or
pravastatin) in hypercholesterolemic patients using angiotensin-converting1999;83:1497–9. A1498.
22] Abhayaratna WP,  Seward JB, Appleton CP, et al. Left atrial size: physiologic
determinants and clinical applications. Journal of the American College of Car-
diology 2006;47:2357–63.
